<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324129</url>
  </required_header>
  <id_info>
    <org_study_id>0103-003</org_study_id>
    <nct_id>NCT00324129</nct_id>
  </id_info>
  <brief_title>A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose In Patients With Leukemia Or Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, MGCD0103, a new anticancer drug under investigation, is given three times&#xD;
      weekly to patients with leukemia or myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I dose escalating study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>1 year (anticipated)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>1 year (anticipated)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>1 year (anticipated)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>1 year (anticipated)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (histone acetylation, biomarkers)</measure>
    <time_frame>1 year (anticipated)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD0103</intervention_name>
    <description>MGCD0103 given orally three times per week.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a diagnosis of one of the following:&#xD;
&#xD;
               -  relapsed or refractory AML or ALL that has failed to respond to standard therapy,&#xD;
                  has progressed despite standard therapy&#xD;
&#xD;
               -  relapsed or refractory Myelodysplastic Syndromes&#xD;
&#xD;
               -  previously untreated AML or Myelodysplastic Syndromes in patients &gt; 60 years of&#xD;
                  age who refused or are not candidates for induction chemotherapy&#xD;
&#xD;
          -  Patients with relapsed or refractory CML that has failed to respond to Imatinib&#xD;
             therapy or standard therapy, has progressed despite standard therapy, or for which no&#xD;
             standard therapy exists&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Patients or their legal representative must be able to read, understand, and sign a&#xD;
             written informed consent (approved by the IRB/EC) prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of another cancer other than basal cell carcinoma or cervical&#xD;
             intraepithelial neoplasia&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients and their partners, if either are of childbearing potential, not using&#xD;
             adequate birth control measures throughout the study and for 90 days following the&#xD;
             last dose of study medication&#xD;
&#xD;
          -  Patients with known meningeal metastasis(es)&#xD;
&#xD;
          -  Patients with active or uncontrolled infections, or with a fever &gt;38.5 C&#xD;
&#xD;
          -  Patients with serious illnesses, medical conditions, or other medical history, which&#xD;
             would be likely to interfere with a patient's participation in the study&#xD;
&#xD;
          -  Patients who have been treated with any investigational drug or anti-cancer therapy&#xD;
             within 30 days of study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Reid, MSc, MBA</last_name>
    <role>Study Director</role>
    <affiliation>MethylGene Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer Davis-Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>May 8, 2006</study_first_submitted>
  <study_first_submitted_qc>May 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <name_title>Gregory Reid, Chief Medical Officer</name_title>
    <organization>MethylGene, Inc.</organization>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mocetinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

